Investors

Investors

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

Latest Press Releases

Date Title and Summary
Toggle Summary Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race
REDWOOD CITY, Calif. , Dec. 10, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple Oncotype DX Breast Recurrence Score ® (RS) presentations at the 2018 San Antonio Breast Cancer Symposium ® (SABCS), reinforcing the value of the Oncotype DX ® test in
Toggle Summary Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test
REDWOOD CITY, Calif. and MECHELEN, Belgium , Dec. 3, 2018 /PRNewswire/ --  Genomic Health , Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced they have
Toggle Summary New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Benefit from Chemotherapy, Reinforcing the Conclusions of the Landmark TAILORx Study
Published Results Underscore Value of Oncotype DX® Test in Identifying Women with Early-stage Breast Cancer Who May Receive Life-saving Benefit from Chemotherapy REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ -- Genomic Health , Inc.  (NASDAQ: GHDX)  and the NSABP Foundation today announced the
Toggle Summary Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test
REDWOOD CITY, Calif. , Nov. 19, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present results from two large studies of the Oncotype DX Breast Recurrence Score ® test at the 2018 San Antonio Breast Cancer Symposium ® (SABCS), which will be held December 4-8 .

DISCLAIMER

The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.